Bisphosphonates and gastrointestinal cancers

Authors’ reply to Abrahamsen and colleagues

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1518 (Published 12 March 2013)
Cite this as: BMJ 2013;346:f1518

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Yana Vinogradova, research fellow in medical statistics1,
  2. Carol Coupland, associate professor and reader in medical statistics1,
  3. Julia Hippisley-Cox, professor of clinical epidemiology and general practice1
  1. 1Division of Primary Care, University Park, Nottingham NG2 7RD, UK
  1. yana.vinogradova{at}nottingham.ac.uk

Pazianas and colleagues’ study did show a 31% reduced risk of incident colorectal cancer in alendronate users compared with non-users (adjusted hazard ratio 0.69, 95% CI 0.60 to 0.79),1 2 as we noted.3 The alendronate group in table 2, however, included all women with one or more prescription for alendronate, and …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL